항우울제로 새롭게 등장한 ‘남용 물질’ - 약리학적 기전, 항우울 효과, 오남용 가능성에 대한 고찰

키워드

참고문헌 (113)

1. clinical psychiatry, "Kaplan and Sadock’s synopsis of psychiatry : behavioral sciences", pp.2015, Sadock BJ
2. Khantzian EJ, "The self-medication hypothesis of addictive disorders : focus on heroin and cocaine dependence", Am J Psychiatry, 142, pp.1259~1264 (1985)
3. Grant BF, "Comorbidity between DSM-IV alcohol use disorders and major depression : results of a national survey", Drug Alcohol Depend, 39, pp.197~206 (1995)
4. Foster JH, "Quality of life in alcohol-dependent subjects--a review", Qual Life Res, 8, pp.255~261 (1999)
5. Paljärvi T, "Binge drinking and depressive symptoms : a 5-year population-based cohort study", Addiction, 104, pp.1168~1178 (2009)
6. Wolitzky-Taylor K, "Longitudinal investigation of the impact of anxiety and mood disorders in adolescence on subsequent substance use disorder onset and vice versa", Addict Behav, 37, pp.982~985 (2012)
7. Voineskos D, "Management of treatment-resistant depression : challenges and strategies", Neuropsychiatr Dis Treat, 16, pp.221~234 (2020)
8. Singh JB, "Approval of esketamine for treatment-resistant depression", Lancet Psychiatry, 7, pp.232~235 (2020)
9. Satel SL, "Stimulants in the treatment of depression : a critical overview", J Clin Psychiatry, 50, pp.241~249 (1989)
10. Ashton H, "The seed and the soil: effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man", Br J Clin Pharmacol, 12, pp.705~720 (1981)
11. Shearman LP, "Antidepressant-like and anorectic effects of the cannabinoid CB1receptor inverse agonist AM251 in mice", Behav Pharmacol, 14, pp.573~582 (2003)
12. Serafini G, "The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review", Int J Mol Sci, 19, pp.2410~ (2018)
13. Johnson MW, "Potential therapeutic effects of psilocybin", Neurotherapeutics, 14, pp.734~740 (2017)
14. Domino EF, "History and pharmacology of PCP and PCP-related analogs", J Psychedelic Drugs, 12, pp.223~227 (1980)
15. Jansen KL, "A review of the nonmedical use of ketamine: use, users and consequences", J Psychoactive Drugs, 32, pp.419~433 (2000)
16. Lee EN, "The effects of low-dose ketamine on acute pain in an emergency setting : a systematic review and meta-analysis", PLoS One, 11, pp.e0165461~ (2016)
17. Jouguelet-Lacoste J, "The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia : a review of the current literature", Pain Med, 16, pp.383~403 (2015)
18. Lauritsen C, "Intravenous ketamine for subacute treatment of refractory chronic migraine : a case series", J Headache Pain, 17, pp.106~ (2016)
19. Grunwell JR, "Procedural sedation outside of the operating room using ketamine in 22,645 children: a report from the pediatric sedation research consortium", Pediatr Crit Care Med, 17, pp.1109~1116 (2016)
20. Wilkinson ST, "A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders", Am J Psychiatry, 174, pp.695~696 (2017)
21. Caddy C, "Ketamine and other glutamate receptor modulators for depression in adults", Cochrane Database Syst Rev, 9, pp.CD011612~ (2015)
22. Sassano-Higgins S, "A review of ketamine abuse and diversion", Depress Anxiety, 33, pp.718~727 (2016)
23. Varì MR, "Ketamine : from prescription anaesthetic to a new psychoactive substance", Curr Pharm Des, 28, pp.1213~1220 (2022)
24. "NARCOTICS CONTROL ACT"[URL]
25. Berman RM, "Antidepressant effects of ketamine in depressed patients", Biol Psychiatry, 47, pp.351~354 (2000)
26. Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
27. Molero P, "Antidepressant efficacy and tolerability of ketamine and esketamine : a critical review", CNS Drugs, 32, pp.411~420 (2018)
28. Krystal JH, "Ketamine : a paradigm shift for depression research and treatment", Neuron, 101, pp.774~778 (2019)
29. Mathew SJ, "Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial", Int J Neuropsychopharmacol, 13, pp.71~82 (2010)
30. Ibrahim L, "Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole:results from a 4-week, double-blind, placebo-controlled study", Neuropsychopharmacology, 37, pp.1526~1533 (2012)
31. Zeilhofer HU, "Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons", Eur J Pharmacol, 213, pp.155~158 (1992)
32. Lapidus KA, "A randomized controlled trial of intranasal ketamine in major depressive disorder", Biol Psychiatry, 76, pp.970~976 (2014)
33. Kim J, "Esketamine for treatment-resistant depression—first FDA-approved antidepressant in a new class", N Engl J Med, 381, pp.1~4 (2019)
34. 김병수, "케타민의 항우울 효과와 임상적 적용", 생물치료정신의학, 26(2), pp.79~87 (2020), 대한생물치료정신의학회[DOI]
35. Jelen LA, "Ketamine for depression", Int Rev Psychiatry, 33, pp.207~228 (2021)
36. Morgan CJ, "Independent Scientific Committee on Drugs. Ketamine use: a review", Addiction, 107, pp.27~38 (2012)
37. Li JH, "To use or not to use : an update on licit and illicit ketamine use", Subst Abuse Rehabil, 2, pp.11~20 (2011)
38. Horowitz MA, "Are we repeating mistakes of the past? A review of the evidence for esketamine", Br J Psychiatry, 219, pp.614~617 (2021)
39. Baudot J, "Safety concerns on the abuse potential of esketamine : multidimensional analysis of a new anti-depressive drug on the market", Fundam Clin Pharmacol, 36, pp.572~581 (2022)
40. Niciu MJ, "Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression", J Affect Disord, 232, pp.310~315 (2018)
41. Short B, "Development of the ketamine side effect tool (KSET)", J Affect Disord, 266, pp.615~620 (2020)
42. McShane R, "Esketamine and the need for a new type of registry for drugs with abuse potential", Am J Psychiatry, 176, pp.966~ (2019)
43. Murrough JW, "Antidepressant efficacy of ketamine in treatmentresistant major depression : a two-site randomized controlled trial", Am J Psychiatry, 170, pp.1134~1142 (2013)
44. Gastaldon C, "Esketamine for treatment resistant depression: a trick of smoke and mirrors?", Epidemiol Psychiatr Sci, 29, pp.e79~ (2019)
45. Salahudeen MS, "Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review", Ther Adv Drug Saf, 11, pp.2042098620937899~ (2020)
46. Farrell M, "Responding to global stimulant use : challenges and opportunities", Lancet, 394, pp.1652~1667 (2019)
47. Corp SA, "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder", J Clin Psychiatry, 75, pp.1010~1018 (2014)
48. 남범우, "정신자극제의 올바른 사용", 대한의사협회지, 61(8), pp.502~508 (2018), 대한의사협회[DOI]
49. Andrew BN, "The use of methylphenidate for physical and psychological symptoms in cancer patients : a review", Curr Drug Targets, 19, pp.877~887 (2018)
50. Mintzer J, "Effect of methylphenidate on apathy in patients with Alzheimer disease : the ADMET 2 randomized clinical trial", JAMA Neurol, 78, pp.1324~1332 (2021)
51. Nierenberg AA, "Dopaminergic agents and stimulants as antidepressant augmentation strategies", J Clin Psychiatry, 59(Suppl 5), pp.60~63 (1998)[DOI]
52. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT)2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
53. Bahji A, "Comparative efficacy and safety of stimulant-type medications for depression : a systematic review and network meta-analysis", J Affect Disord, 292, pp.416~423 (2021)
54. Rabiner DL, "Predictors of nonmedical ADHD medication use by college students", J Atten Disord, 13, pp.640~648 (2010)
55. Kolar D, "Alertness in patients with treatment-resistant depression : interface between sleep medicine and psychiatry—review article", Middle East Curr Psychiatry, 28, pp.42~ (2021)
56. Benson K, "Symptoms of depression and ADHD in relation to stimulant medication misuse among college students", Subst Use Misuse, 52, pp.1937~1945 (2017)
57. 안유석, "ADHD 및 성인 ADHD에 대한 개념적 고찰 (2): ADHD의 정신병리와 진단 및 치료의 함의", 신경정신의학, 61(2), pp.45~62 (2022), 대한신경정신의학회[DOI]
58. Katzman MA, "Adult ADHD and comorbid disorders : clinical implications of a dimensional approach", BMC Psychiatry, 17, pp.302~ (2017)
59. Zullig KJ, "The association between non-medical prescription drug use, depressive symptoms, and suicidality among college students", Addict Behav, 37, pp.890~899 (2012)
60. Faraone SV, "Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies", J Am Acad Child Adolesc Psychiatry, 59, pp.100~112 (2020)
61. Safer DJ, "Recent trends in stimulant usage", J Atten Disord, 20, pp.471~477 (2016)
62. Park G, "Trends in diagnosis and prescription of ADHD in Korea:implications in the respect of medicalization", pp.2016
63. Chinneck A, "Personality and prescription drug use", misuse among first year undergraduates, 2018, pp.87, 122~130
64. Woicik PA, "The substance use risk profile scale : a scale measuring traits linked to reinforcementspecific substance use profiles", Addict Behav, 34, pp.1042~1055 (2009)
65. Degenhardt L, "Extent of illicit drug use and dependence, and their contribution to the global burden of disease", Lancet, 379, pp.55~70 (2012)
66. Lev-Ran S, "Cannabis use and cannabis use disorders among individuals with mental illness", Compr Psychiatry, 54, pp.589~598 (2013)
67. Turna J, "Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?", Depress Anxiety, 34, pp.1006~1017 (2017)
68. Woo JJ, "Children and youth who use Cannabis for pain relief: benefits, risks, and perceptions", Adolesc Health Med Ther, 11, pp.53~61 (2020)
69. "Shocking update on Thailand legalizing marijuana"[URL]
70. Gruber AJ, "Do patients use marijuana as an antidepressant?", Depression, 4, pp.77~80 (1996)
71. Osborn LA, "Self-medication of somatic and psychiatric conditions using botanical marijuana", J Psychoactive Drugs, 47, pp.345~350 (2015)
72. Grotenhermen F, "Pharmacology of cannabinoids", Neuro Endocrinol Lett, 25, pp.14~23 (2004)
73. Sommano SR, "Growing ganja permission : a real gate-way for Thailand’s promising industrial crop?", J Cannabis Res, 4, pp.10~ (2022)
74. Chadwick VL, "Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans", Curr Opin Psychiatry, 33, pp.20~42 (2020)
75. Lev-Ran S, "The association between cannabis use and depression : a systematic review and meta-analysis of longitudinal studies", Psychol Med, 44, pp.797~810 (2014)
76. Chen CY, "Marijuana use and the risk of major depressive episode. Epidemiological evidence from the United States National Comorbidity Survey", Soc Psychiatry Psychiatr Epidemiol, 37, pp.199~206 (2002)
77. Danielsson AK, "Cannabis use, depression and anxiety: a 3-year prospective populationbased study", J Affect Disord, 193, pp.103~108 (2016)
78. Feingold D, "The association between cannabis use and mood disorders : a longitudinal study", J Affect Disord, 172, pp.211~218 (2015)
79. Feingold D, "Cannabis and depression", Adv Exp Med Biol, 1264, pp.67~80 (2021)
80. Henquet C, "Cannabis use and expression of mania in the general population", J Affect Disord, 95, pp.103~110 (2006)
81. Carvalho AF, "Cannabis use and suicide attempts among 86,254 adolescents aged 12-15 years from 21 low- and middle-income countries", Eur Psychiatry, 56, pp.8~13 (2019)
82. 김병수, "대마의 정신의학적 영향", 생물치료정신의학, 25(3), pp.183~191 (2019), 대한생물치료정신의학회[DOI]
83. Peciña M, "Endogenous opioid system dysregulation in depression : implications for new therapeutic approaches", Mol Psychiatry, 24, pp.576~587 (2019)
84. 윤동욱, "만성 비암성 통증 환자의 아편유사제 사용", 신경정신의학, 58(3), pp.182~191 (2019), 대한신경정신의학회[DOI]
85. 조윤숙, "단일 상급종합병원에서 마약성 진통제의 최근 13년간 사용 경향 조사", 약 학 회 지, 58(4), pp.268~276 (2014), 대한약학회
86. Volkow ND, "Opioid abuse in chronic pain—misconceptions and mitigation strategies", N Engl J Med, 374, pp.1253~1263 (2016)
87. Karp JF, "Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults", J Clin Psychiatry, 75, pp.e785~e793 (2014)
88. Browne CA, "Targeting opioid dysregulation in depression for the development of novel therapeutics", Pharmacol Ther, 201, pp.51~76 (2019)
89. Gabilondo AM, "Increased density of mu-opioid receptors in the postmortem brain of suicide victims", Brain Res, 682, pp.245~250 (1995)
90. Kosten TR, "An opioid for depression?", Am J Psychiatry, 173, pp.446~447 (2016)
91. Schatzberg AF, "Opioids in psychiatric disorders : back to the future?", Am J Psychiatry, 173, pp.564~565 (2016)
92. Yovell Y, "Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation : a randomized controlled trial", Am J Psychiatry, 173, pp.491~498 (2016)
93. Rogers AH, "Association of opioid misuse with anxiety and depression : a systematic review of the literature", Clin Psychol Rev, 84, pp.101978~ (2021)
94. Sullivan MD, "Why does depression promote long-term opioid use?", Pain, 157, pp.2395~2396 (2016)
95. Leeies M, "The use of alcohol and drugs to self-medicate symptoms of posttraumatic stress disorder", Depress Anxiety, 27, pp.731~736 (2010)
96. Bodkin JA, "Buprenorphine treatment of refractory depression", J Clin Psychopharmacol, 15, pp.49~57 (1995)
97. Nichols DE, "Psychedelics", Pharmacol Rev, 68, pp.264~355 (2016)
98. MacLean KA, "Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness", J Psychopharmacol, 25, pp.1453~1461 (2011)
99. Gallimore AR, "Restructuring consciousness-the psychedelic state in light of integrated information theory", Front Hum Neurosci, 9, pp.346~ (2015)
100. Griffiths RR, "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects", Psychopharmacology (Berl), 218, pp.649~665 (2011)
101. Passie T, "The pharmacology of psilocybin", Addict Biol, 7, pp.357~364 (2002)
102. Nichols DE, "Psilocybin: from ancient magic to modern medicine", J Antibiot (Tokyo), 73, pp.679~686 (2020)
103. Goldberg SB, "The experimental effects of psilocybin on symptoms of anxiety and depression : a meta-analysis", Psychiatry Res, 284, pp.112749~ (2020)
104. Carhart-Harris R, "Trial of psilocybin versus escitalopram for depression", N Engl J Med, 384, pp.1402~1411 (2021)
105. Griffiths RR, "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with lifethreatening cancer : a randomized double-blind trial", J Psychopharmacol, 30, pp.1181~1197 (2016)
106. De Gregorio D, "Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine", J Neurosci, 41, pp.891~900 (2021)
107. Carhart-Harris RL, "Neural correlates of the LSD experience revealed by multimodal neuroimaging", Proc Natl Acad Sci U S A, 113, pp.4853~4858 (2016)
108. Mertens LJ, "Therapeutic mechanisms of psilocybin : changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression", J Psychopharmacol, 34, pp.167~180 (2020)
109. Kraehenmann R, "Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers", Biol Psychiatry, 78, pp.572~581 (2015)
110. Roseman L, "Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression", Neuropharmacology, 142, pp.263~269 (2018)
111. Fantegrossi WE, "Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys", Behav Pharmacol, 15, pp.149~157 (2004)
112. de Veen BT, "Psilocybin for treating substance use disorders?", Expert Rev Neurother, 17, pp.203~212 (2017)
113. Johnson M, "Human hallucinogen research : guidelines for safety", J Psychopharmacol, 22, pp.603~620 (2008)

관련 논문AI추천